Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP1 | O94782 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730614 | 0.83 | MKNK1 (0.46) | GRM2KDM1AALOX5APFEN1PARP15 | |
| SCHEMBL15723943 | 0.81 | NPC1 (0.46) | TDP1 | |
| SCHEMBL17067048 | 0.81 | DRD2 (0.41) | KDM1AALOX5APFEN1PARP15PARP10 | |
| SCHEMBL15723947 | 0.80 | HRH3 (0.39) | GPR88ALOX5APFEN1FFAR4 | |
| SCHEMBL24499201 | 0.79 | RIPK1 (0.46) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15723893 | 0.77 | CLK4 (0.55) | — | |
| SCHEMBL15723929 | 0.77 | CYP2D6 (0.40) | USP1FFAR4 | |
| SCHEMBL15723911 | 0.76 | MAP4K4 (0.43) | ALOX5APFEN1FFAR4 | |
| SCHEMBL15723934 | 0.74 | GAA (0.36) | ALOX5APFEN1 | |
| SCHEMBL22479953 | 0.74 | MCHR1 (0.46) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | GRM2 4719/4885KDM1A 1820/4885GPR88 2646/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | GRM2 4719/4885KDM1A 1820/4885GPR88 2646/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | GRM2 4719/4885KDM1A 1820/4885GPR88 2646/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | GRM2 4719/4885KDM1A 1820/4885GPR88 2646/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | GRM2 4719/4885KDM1A 1820/4885GPR88 2646/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | GRM2 4719/4885KDM1A 1820/4885GPR88 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.